Rheumatology 2006;45:20–25

doi:10.1093/rheumatology/kei111

Advance Access publication 27 September 2005

Review Article

Use and significance of anti-CCP autoantibodies
in rheumatoid arthritis

A. J. W. Zendman, W. J. van Venrooij and G. J. M. Pruijn

One of the most common autoimmune diseases is rheumatoid
arthritis (RA), affecting 0.5–1% of the population. This systemic
disease is marked by chronic inflammation of synovial joints,
which leads to destruction of cartilage and bone and eventually
to disability of the patient [1]. Though not directly life-
threatening, RA severely affects the quality of life of a patient
and

also

has

major

economic

consequences

for

society.

Therefore, every attempt should be made to prevent the erosive
processes to occur. Currently, the classification of RA relies
mainly on the criteria described by the American College of
Rheumatology (ACR) [2]. These criteria, originally formulated
50 yr ago and last adjusted in 1987, are based mainly on clinical
parameters. Since these parameters are often only sufficiently
fulfilled when the damaging effects of the inflammatory process
are already in progress, this set of criteria is not very suitable for
the early diagnosis of RA [3].

The key to early recognition of autoimmunity lies within

the humoral immune system. Since blood samples are taken
from clinic-visiting

(pre-)patients, screening for serological

RA-indicators can be performed quite easily. In the ACR
criteria for RA one serological marker is included: rheumatoid
factor (RF). The RF autoantibody system, directed against the Fc
part of immunoglobulin (Ig) G molecules, has had a central role
in the diagnosis and prognosis of RA during recent decades [4]
because RF can be detected in the majority of RA patients.
However, it is becoming more and more clear that the presence
of RF is not restricted to patients with RA, but that it can also
be detected in subsets of patients suffering from other diseases
and even in a percentage of healthy (especially elderly)
individuals [5]. The resulting lack of specificity for RA can
lead to confusion and unwanted treatment. The shortcomings of
the RF test have kept the search for more specific RA markers
alive. Most autoantibody systems described during recent
decades have failed to mature into mainstream tests for RA
because of low sensitivity, lack of specificity or technical
inconvenience, as reviewed previously [6–8]. The only antibody
system that combines good sensitivity with superior specificity
for RA is that targeting citrullinated epitopes. This review will
focus mainly on the diagnostic potential of the second-generation
anti-cyclic citrullinated peptide (CCP) test (CCP2) for RA. Next,
we will address the prognostic ability of the anti-CCP test. The
presence of these antibodies early in disease development opens
a window of opportunity for early custom-tailored treatment
of RA. Finally, we will review the effect of disease treatment on
anti-CCP levels and briefly go into the putative functional role
of these antibodies in the chronic aspects of RA.

From APF to CCP2

The autoantibody system most specific for RA known to date
is that directed to citrullinated antigens. The citrulline moiety,
which is the essential part of the antigenic determinant in these
antigens, is post-translationally generated by peptidylarginine
deiminases (PAD; EC 3.5.3.15) [9]. RA autoantibodies against
citrullinated antigens have been detected and used for diagnostic
purposes for many decades via the well-known antiperinuclear
factor (APF) [10] and antikeratin antibody (AKA) tests [11].
Supported by the fact that APF and AKA share many features,
as reviewed previously [12], and are reactive with native filaggrin,
these

autoantibodies

are

now

designated

as

antifilaggrin

antibodies (AFA) [13]. Using the laborious and inconvenient
immunofluorescence assay, roughly 50% of RA sera can be
scored AFA-positive. A key finding was the discovery that the
reactivity of these AFA was completely dependent on the presence
of citrulline residues (present in mature filaggrin but not in
profilaggrin) [14, 15]. Since then, two approaches for detecting
autoantibodies to citrullinated epitopes have been taken: a
protein-based and a peptide-based approach.

Screening for citrulline-specific RA reactivity has been per-

formed with several proteins, including both purified naturally
occurring citrullinated proteins and in vitro-citrullinated proteins.
For these purposes, mainly filaggrin, fibrinogen and myelin basic
protein have been used. Although most of these proteins
are arginine-rich, there is obviously a limit to the number
of citrullinated epitopes associated with a certain protein. A
complication of the use of natural antigens is that it is difficult
to obtain reasonable amounts in sufficient purity in a repro-
ducible way. Batch-to-batch variation also compromises stan-
dardization when in vitro citrullination is used to generate the
antigen. Insufficient purity of the antigen lowers the specificity
of the test because reactivities directed to other components
(e.g. the PAD enzyme, the non-citrullinated part of the antigen,
other contaminants) may be detected as well. The use of proper
(non-citrullinated) controls is therefore very important, as indeed
has been noted by Vittecoq and colleagues [16]. Interestingly,
autoantigenicity of the PAD protein has recently been described,
but this reactivity is not specific for RA [17]. However, despite
these limitations several studies have successfully improved the
sensitivity of AFA detection while maintaining specificity levels
[18]. Using various technologies, assays with various sources of
filaggrin have been developed, allowing sensitivities up to 60%
[16, 19, 20]. Using citrullinated fibrinogen, Nielen and colleagues
[21] reported a similar sensitivity (56%) for a cohort of early
arthritis patients.

Correspondence to: A. J. W. Zendman, Department of Biochemistry, NWI 161, Radboud University Nijmegen, PO Box 9101, 6500 HB, Nijmegen,

The Netherlands. E-mail: [e-mail]

Department of Biochemistry, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands.

Received 2 June 2005; revised version accepted 9 August 2005.

ß The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [e-mail]

20

The use of synthetic citrullinated peptides for anti-citrullinated

protein

antibody

detection

can

overcome

many

of

the

complicating factors of the protein-based approach. Synthetic
peptide

production

and

purification

is

cheap

and

easily

standardized, and via peptides one can synthesize an unlimited
pool of defined epitopes. Furthermore, citrulline residues can
be incorporated during synthesis of the peptides, leading to a
homogeneous preparation of citrullinated molecules. A major
breakthrough came with the development of an enzyme-linked
immunosorbent assay (ELISA) that used filaggrin-based citrulli-
nated peptides [14]. The reactivity of RA sera was completely
dependent on the citrulline residue(s) present, since the same
peptides in which the citrulline was replaced by another amino
acid were not antigenic. The variation in reactivity patterns
against different citrullinated peptides clearly showed that the
anti-CCP response in RA is polyclonal. When a filaggrin-based
cyclic peptide (cyclization increased the sensitivity) was applied
in the first generation anti-CCP (CCP1) test, a sensitivity of
68% was obtained with very high specificity for RA (98%) [22].
Though better than the protein-based methods, the sensitivity
was not as high as that of the routinely used RF test. Because
filaggrin is not present in the synovium, dedicated libraries
of citrulline-containing peptides were screened with RA sera to
select for superior epitopes. This culminated in the CCP2 test,
which displays a sensitivity of up to 80% without loss of
specificity.

Anti-CCP2 autoantibodies as diagnostic markers

Diagnostic markers of disease ideally fulfil three requirements:
(i) good sensitivity, to detect a high percentage of patients;
(iii) good specificity, to limit false-positive results as much as
possible; and (iii) early presence, to facilitate early diagnosis.

Over the last decade many studies have investigated the

diagnostic performance of the anti-CCP test. Those using the
CCP1 test have been reviewed by van Boekel and colleagues [6].
Increasing

data

on

the

improved

[23]

second-generation

anti-CCP test show that the CCP2 test result is a good
diagnostic parameter for (early) RA.

Sensitivity/specificity

The first large cohort studies of anti-CCP2 as a diagnostic
marker showed that anti-CCP2 combines RF-like sensitivity with
almost absolute specificity for RA [5, 24, 25]. These multicentre
studies showed that anti-CCP2 antibodies, just like RF, are
present in about 80% of established RA patients. In the healthy
control group and the non-RA disease controls, the CCP2
test was only positive in maximally 1 and 5%, respectively.
The corresponding percentages of the RF (over 10% of healthy
controls and more than 20% of disease controls) were markedly
higher [5, 25]. Several recent independent studies confirmed these
sensitivity/specificity data for CCP2 [26–30]. Using a cohort of
549 RA patients, the study of Suzuki and colleagues [26] clearly
showed higher discriminative ability for the CCP2 test than for
RF test. The reported sensitivity of 65% (at 96% specificity)
by Dubucquoi and colleagues [27] was found in a group of
RA patients that included several patients with recent onset of
disease. The sensitivity in their established RA patient group was
77%. Overall, the observed intercohort variations in these studies
might be explained by differences in the characteristics of the
patients that were included. One study reported a somewhat
lower specificity for RA of about 90% with the CCP2 test [31],
but this could have been caused by the fact that the juvenile RA
(JRA) group included in this study might have contained several
adult RA patients with an early onset of disease, as discussed
previously [32]. The JRA patients had a high average age (31 yr)

and often longstanding disease (21 yr on average), mostly
resulting in erosions (87%). A striking example of the diagnostic
performance of the CCP2 test is the recent study by de Rycke
and colleagues [28]. Setting the specificity values for RA at
98.5% resulted in a sensitivity for RF of only 12.8% compared
with 73.7% for anti-CCP2.

Taken together, these studies show that the anti-CCP2 test

at least equals the RF level for sensitivity, but combines this
with far better specificity. The fact that around 40% of
RF-seronegative

patients

appear

to

be

anti-CCP-positive

substantiates the additional diagnostic potential of CCP [29, 33].

The anti-CCP test also enables clinicians to effectively

distinguish RA patients from other arthritic diseases in cases
where the RF is not always discriminative. One of the first
examples of such a role in differential diagnosis comes from
patients with erosive systemic lupus erythematosus (SLE).
Mediwake and colleagues [34] showed that anti-CCP (in this
case CCP1) can be used to distinguish RA patients from
SLE patients who present with erosive polyarthritis, which is
often accompanied by RF seropositivity. Another disease that
can readily be misdiagnosed because it often reveals RA-like
arthropathies is chronic hepatitis C virus (HCV) infection, which
is often accompanied by a positive RF. Wener et al. [35] reported
a good discriminative ability of anti-CCP2 over RF in a group
of randomly selected HCV patients (44% RF

þ

, none CCP2

þ

).

These data were confirmed by Bombardieri and colleagues [36].
Whereas RF was detected in 15% of the HCV patients (37% in
case of joint involvement), no anti-CCP2 positivity was seen
in these patients. The value of anti-CCP for use in differential
diagnosis was also shown when comparing RA patients with
polymyalgia rheumatica patients [37]. Taken together, these
data clearly outline the diagnostic strength of the anti-CCP test
for RA.

Recently, some papers have reported anti-CCP positivity in

arthritic diseases that share certain features with RA [38–40]. In
palindromic arthritis (PR), a percentage of anti-CCP positivity
(56%) similar to that of patients with early RA (55%) was found
[38]. PR is a relapsing from of arthritis that shares many features
of RA. In addition to the observed anti-CCP reactivity, many of
these sera are also RF-positive (30–60%). Moreover, as is the
case for RA, PR is associated with the presence of the MHC
shared epitope (odds ratio of 2.9) [41]. The current assumption
is that PR is an abortive form of RA that in a percentage of
patients may develop into RA. The presence of RF in PR has
already been shown to be associated with the development of
chronic disease [42]. Regarding the prognostic significance of
anti-CCP positivity in PR and the possible development of RA,
additional studies with larger cohorts and longer follow-up are
needed.

In patients with primary Sjo¨gren’s syndrome, anti-CCP

reactivity was detectable in 8% of the 134 patients tested [39].
For another RA-like disease, psoriatic arthritis, the group of
de Rycke [40] found anti-CCP positivity in 8% of the 192
patients tested. This reactivity, confirmed with an additional test
using home-made citrullinated peptides, was higher than could
be ascribed to simple overlap with RA. These studies make clear
that, especially in RA-like arthritic disease entities, further
clinical follow-up is needed to establish whether the anti-CCP
positivity predicts the development of RA.

Early presence and predictive potential

Because RA patients at their first visit to the clinician often do
not fulfil the criteria for the diagnosis/classification of RA, an
early detectable, highly predictive marker would greatly help the
clinician in reaching a diagnosis. Obviously, the sensitivity and
specificity of such a marker should be as high as possible.
Recently, two studies, both making use of dated samples from

Diagnostic potential of CCP2 test for RA

21

RA patients who were former blood donors, reported the
presence of anti-CCP antibodies prior to the appearance of the
first clinical symptoms of arthritis [43, 44]. Samples from 72
blood donors were characterized by Nielen and colleagues [43]
for positivity of IgM-RF or anti-CCP1. Both serological markers
were detectable long before the disease became clinically overt.
In some patients, anti-CCP1 was found up to 14 yr prior to the
first clinical symptoms of disease. The same was found for 39%
of the patients 5.3 yr (median) before the first visit to the clinic.
IgM-RF was also found in predisease samples, but not as far
back (up to 10 yr) and in a smaller percentage of patients (23%
at a median of 3.3 yr). The second study, with a similar set-up,
detected anti-CCP2 and RF up to 10 yr before clinical disease
in predisease blood samples of 83 RA patients. Anti-CCP2
positivity gradually increased in the years prior to the first
clinical symptoms and had reached a positivity of 70% at the
time the patients visited the rheumatology clinic for the first
time. The sensitivity for detecting RF autoantibodies in these
predisease samples was slightly less than for anti-CCP2 [44].
From these studies it is clear that the production of anti-CCP
and RF autoantibodies is an early process in RA development,
and that their presence is predictive for the development of this
disease.

Recent data from several longitudinal studies confirm the

predictive ability of anti-CCP2 for RA development [16, 45, 46].
van Gaalen and colleagues [45] used serological markers to
predict which of the patients attending an early arthritis clinic,
who were classified as undifferentiated arthritis (UA), would
progress to RA within the next few years. Follow-up data of
318 patients with UA clearly showed the predictive potential of
anti-CCP autoantibodies for the development of RA. After 1 yr
of follow-up, 75% of the UA patients who were anti-CCP2-
positive at baseline had already progressed to RA. This
percentage increased to 93% after 3 yr (odds ratio 38). Of the
UA group who were anti-CCP2 negative at baseline, only 25%
were classified RA after 3 yr. Similar results were reported by
Vittecoq and colleagues [16]. In their cohort of 314 early arthritis
patients, 90% of the anti-CCP2-positive patients were classified
as RA patients at the 1-yr follow-up. Thus, the combined
early presence and predictive ability of anti-CCP may find an
important clinical application in the design of treatment
strategies.

Anti-CCP2 autoantibodies as a prognostic marker

Various studies have addressed the prognostic value of anti-CCP
antibodies. Though the anti-CCP test has only recently become
widely available, several studies have already demonstrated its
ability to predict the erosiveness of developing RA. Most of
these studies used the CCP1 test and the results of these have
been discussed previously [32, 47]. An increasing number of
studies with anti-CCP2 confirm the prognostic potential. First, in
a cohort of 379 early RA patients, Forslind and colleagues [48]
showed that anti-CCP2 positivity at baseline (55%) predicts
radiological damage and progression at 2 yr follow-up. Similar
results were obtained by Kastbom and colleagues [49]. In their
study, CCP2 positivity at baseline predicted disease activity at
the 3-yr follow-up. In addition, Ro¨nnelid et al. [50] showed that
anti-CCP2-positive early RA patients developed worse clinical
disease and greater radiological damage within a few years in
comparison with anti-CCP2-negative patients.

The

prognostic

ability

of

the

anti-CCP

test

is

often

complemented by other disease parameters. With respect to
the presence of the shared epitope MHC class II molecules, this
was reported by independent studies of Berglin et al. [51], van
Gaalen et al. [52], de Rycke et al. [28] and Lindqvist et al. [53].
The study by de Rycke and colleagues also showed that
anti-CCP2 positivity, unlike RF, did not correlate with the

presence

of

extra-articular

manifestations

[28].

Raza

and

colleagues [54] reported that the combination of anti-CCP2
and

RF

positivity

was

the

best

prognosticator

for

the

development of persisting RA in a patient group with very
early synovitis. Anti-CCP2 levels are also associated with the
development of bone erosions in RA [55]. On the other hand,
Gossec et al. [56] reported that there was no significant
correlation between the absence of anti-CCP antibodies and
remission of early RA.

The conclusion from these studies is that a positive anti-CCP

test appears to predict the development of erosive RA and that
this predictive value complements that of RF. Together with
additional individual data (e.g. the presence of shared epitope,
family members with RA), this may lead to a very high
probability that erosive RA is developing.

Effect of therapy on anti-CCP status

Among the most effective drugs for the treatment of RA at
present are those targeting the pro-inflammatory TNF-. TNF-


-inhibiting agents like infliximab can reduce disease activity and

delay radiographic progression of RA [57]. However, side-effects,
such as an increased risk of infections and the induction
of autoantibodies (e.g. antinuclear antibodies or anti-double-
stranded DNA antibodies), have also been reported [58].
The determination of autoantibody levels during the course of
treatment (anti-CCP, RF) may give some clues regarding the
effectiveness of the treatment and the role of these antibodies
in the disease process.

In the past year, several papers have reported effects on

RA-associated markers, including anti-CCP, in patients treated
with disease-modifying anti-rheumatic drugs (DMARDs) [mainly
methotrexate (MTX)] with [59–63] or without [50, 64] infliximab
(summarized in Table 1). Bobbio-Pallavicini and colleagues [59]
studied autoantibody profiles during long-term (78 weeks)
combination treatment with infliximab and MTX. Though
treatment resulted in a significant decrease in disease activity
scores, no changes in the percentages of patients who were
positive for anti-CCP2 or IgM-RF were observed. Titres of RF,
on the other hand, were significantly reduced, unlike those of
anti-CCP. These results were confirmed by several other studies,
although follow-up periods varied between the individual studies
(Table 1). In the study of Nissinen and colleagues [60], anti-CCP
(measured by the anti-CCP1 test) did not change during 6 weeks
of follow-up, though 60% of the patients had a significant
clinical response. IgM-RF levels were somewhat decreased in
the first weeks of therapy. With follow-up periods of 22 and
30 weeks, respectively, Caramaschi and colleagues [63] and
de Rycke and colleagues [62] also observed a decrease in RF
levels but not of anti-CCP. In contrast to the previous studies,
Alessandri and colleagues [61] did find a small but significant
decrease in anti-CCP levels at week 24 of treatment in the
patients with clinical improvement. This effect, also observed for
RF, was dependent on infliximab, since reductions in anti-CCP
levels were not observed after treatment with MTX alone.
Nevertheless, DMARD-only therapy can result in a significant
(>25%) reduction in both anti-CCP and RF in about 50% of
patients [64]. In this last study, effective treatment correlated
with a reduction of RF. Recently, Ro¨nnelid and colleagues [50]
showed that treatment with sulphasalazine, but not other
DMARDs, resulted in a drop in anti-CCP levels, but this
decrease occurred only in the first year of follow-up and did not
correlate with clinical indicators.

From these studies, it is clear that the anti-CCP autoantibody

system is different from the RF system with respect to response
to treatment. Clearly, investigating the functional importance of
anti-CCP in the progression of RA demands other approaches
specifically aimed at decreasing this humoral response.

22

A. J. W. Zendman et al.

Putative functional implications for anti-CCP

Because anti-CCP autoantibodies are so specific for RA, one
wonders what they can tell us about the aetiology of the disease.
To answer that question we need to know more about (synovial)
protein citrullination and the PAD enzymes responsible for
the conversion of peptidylarginine to peptidylcitrulline. The
five isoforms of human PAD show a tissue-specific expression
profile [9]. It has been shown that PAD enzymes are present
in the inflamed synovium and that their activity is regulated at
the transcriptional and translational levels [65, 66]. In addition,
these enzymes require relatively high Ca

2þ

concentrations, about

100 times higher than normally present in the cytosol of a living
cell. Interestingly, citrullination occurs primarily in dying cells.
Indeed, during inflammation, when many cells die by apoptosis
or necrosis, one can detect citrullinated proteins, both in animal
models of inflammation and in the inflamed synovia of RA and
non-RA patients. Paradoxically, the presence of citrullinated
proteins in most cases does not lead to the generation of anti-
citrullinated protein antibodies [67, 68]. This phenomenon might
be related to the genetic background of the patient. It has been
known for some time that there is a rather strong correlation
between RA and certain HLA-DR alleles, particularly HLA-
DRB1*0401 and HLA-DRB1*0404. These alleles contain the
so-called shared epitope (SE) motif. Hill and colleagues [69]
showed that the conversion of arginine to citrulline increased the
affinity of a peptide for binding to HLA-DRB1 and can lead to
activation of CD4

þ

T cells in DR4-transgenic mice. These results

thus indicate that the production of anti-citrullinated protein
antibodies is dependent on the presence of certain susceptibility
genes for RA. The fact that the observed odds ratio of 66.8 for
the combination of anti-CCP and SE HLA gene carriage is over
two times the value of the multiplication of the corresponding
single odds ratios (anti-CCP, 15.9; SE, 2.4) also suggests that
these factors are functionally associated [51]. Very recently it was
shown that patients who were homozygous for SE alleles and
seropositive for anti-CCP antibody presented with an increased
rate of joint destruction compared with patients carrying only
one or none of these alleles [52]. Also, these results suggest that
the production of these antibodies stimulates the ongoing
inflammation in RA.

These data have led to a relatively simple model for the

development of RA, depicted in Fig. 1 and discussed previously
[70, 71]. In individuals with a genetic predisposition for RA, an
inflammation of the joint, in itself innocent, leads to infiltration
of inflammatory cells (monocytes, granulocytes) that contain
PAD enzymes. After activation, these cells will die via apoptosis
and will be cleared (removed) by phagocytosing cells. However,
when there is massive apoptosis, or a (genetic) defect in the
clearance system, some apoptotic cells may become necrotic,
thereby releasing citrullinated proteins (histones, vimentin) and
PAD enzymes. The PAD enzymes can subsequently citrullinate
synovial proteins, such as fibrin. In 99% of individuals this
will be the end of the story. In the 1% of individuals who

are able to present fragments of the citrullinated proteins to
the T cells via certain MHC class II molecules, a B-cell
response to citrullinated antigens will be generated, resulting in
the formation of immune complexes which will stimulate the
inflammatory process by upregulation of pro-inflammatory
cytokines. New monocytes and granulocytes will enter the
synovium, will be activated, die, and stimulate a new flare of
inflammation. The repetition of this process over a number of
years, eventually accompanied by fresh traumas or environ-
mental events that stimulate inflammation, will finally lead to a
chronic inflammation which can develop into the disease we
know as rheumatoid arthritis. In this way, anti-CCP contributes
to the perpetuation of joint inflammation and thereby to the
chronicity and severity of RA.

Future perspectives

Currently available therapies for RA, nicely reviewed by Smolen
and Steiner [72], are mainly anti-inflammatory and unable to
cure the disease. At best these therapies are able to slow down
the extent of swelling and erosive damage. More insight obtained
over recent years suggests that combination therapies given
early in the disease have the greatest therapeutic potential [73].
To achieve the ultimate goal of curative treatment, it is crucial
to identify RA patients before joint damage occurs. The fact
that the CCP2 test is now widely available will speed up
these studies, as shown by the burst of data on CCP in the
literature. Knowledge about the citrullinome (total repertoire
of

citrullinated

proteins),

the

application

of

array-based

screening technologies [74] and use in automated assays [75]
will undoubtedly further increase the diagnostic potential of
these autoantibodies.

A.Z. received a grant from the Netherlands Organisation for
Scientific Research. G.P. and W.V. are cofounders and share-
holders of ModiQuest b.v. W.V. serves as a consultant to Euro-
Diagnostica b.v. and Axis shield.

T

ABLE

1. Features of longitudinal studies on anti-CCP status during RA treatment

Study

Reference

Treatment

Cohort

Follow-up

Outcome

Bobbio-Pallavicini

[59]

Infliximab/MTX

39

78 weeks

No effect on anti-CCP levels (87% responders)

Nissinen

[60]

Infliximab/DMARDs

25

6 weeks

No effect on anti-CCP levels (60% responders)

Caramaschi

[63]

Infliximab/MTX

27

22 weeks

No effect on anti-CCP levels (74% responders)

de Rycke

[62]

Infliximab/MTX

62

30 weeks

No effect on anti-CCP levels (100% responders)

Alessandri

[61]

Infliximab/MTX

43

24 weeks

Decrease in anti-CCP in patients with clinical improvement

Mikuls

[64]

DMARDs

208

2 yr

Small anti-CCP reduction in 50% of patients;

no association with response

Ro¨nnelid

[50]

DMARDs

379

5 yr

Anti-CCP stable; only small drop in 1st year

(not correlating with disease)

F

IG

. 1. Hypothesized cycle of RA chronicity.

Diagnostic potential of CCP2 test for RA

23

References

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell

1996;85:307–10.

2. Arnett FC, Edworthy SM, Bloch DA et al. The American

Rheumatism Association 1987 revised criteria for the classification
of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

3. Visser H, le Cessie S, Vos K et al. How to diagnose rheumatoid

arthritis early: a prediction model for persistent (erosive) arthritis.
Arthritis Rheum 2002;46:357–65.

4. Mageed RA. The RF antigen. In: Smolen JS, Kalden JR, Maini RN,

eds. Rheumatoid arthritis. Berlin: Springer-Verlag, 1992:299–318.

5. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/

peptide antibody and its role in the diagnosis and prognosis of early
rheumatoid arthritis. Neth J Med 2002;60:383–8.

6. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ.

Autoantibody systems in rheumatoid arthritis: specificity, sensitivity
and diagnostic value. Arthritis Res 2002;4:87–93.

7. Steiner G, Smolen JS. Autoantibodies in rheumatoid arthritis and

their clinical significance. Arthritis Res 2002;4(Suppl. 2):S1–S5.

8. Marcelletti JF, Nakamura RM. Assessment of serological markers

associated with rheumatoid arthritis: diagnostic autoantibodies and
conventional disease activity markers. Clin Appl Immunol Rev
2003;4:109–23.

9. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD,

a growing family of citrullinating enzymes: genes, features and
involvement in disease. Bioessays 2003;25:1106–18.

10. Nienhuis RL, Mandema E. A new serum factor in patients with

rheumatoid arthritis; the antiperinuclear factor (APF). Ann Rheum
Dis 1964;23:302–5.

11. Young BJ, Mallya RK, Leslie RD et al. Anti-keratin antibodies in

rheumatoid arthritis. In: van Venrooij WJ, Maini RN, eds. Manual
of biological markers of disease. Dordrecht: Kluwer Academic
Publishers 1996:1–27.

12. Hoet RM, van Venrooij WJ. The antiperinuclear factor (APF) and

antikeratin antibodies (AKA) in rheumatoid arthritis. 1992;299–318.

13. Sebbag M, Simon M, Vincent C et al. The antiperinuclear factor

and the so-called antikeratin antibodies are the same rheumatoid
arthritis-specific autoantibodies. J Clin Invest 1995;95:2672–9.

14. Schellekens GA, de Jong BA, van den Hoogen FH et al. Citrulline

is an essential constituent of antigenic determinants recognized by
rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:
273–81.

15. Girbal-Neuhauser E, Durieux JJ, Arnaud M et al. The epitopes

targeted by the rheumatoid arthritis-associated antifilaggrin auto-
antibodies are posttranslationally generated on various sites of
(pro)filaggrin by deimination of arginine residues. J Immunol 1999;
162:585–94.

16. Vittecoq O, Incaurgarat B, Jouen-Beades F et al. Autoantibodies

recognizing citrullinated rat filaggrin in an ELISA using citrullinated
and non-citrullinated recombinant proteins as antigens are highly
diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004;135:
173–80.

17. Nissinen R, Paimela L, Julkunen H et al. Peptidylarginine deiminase,

the arginine to citrulline converting enzyme, is frequently recognized
by sera of patients with rheumatoid arthritis, systemic lupus
erythematosus and primary Sjogren syndrome. Scand J Rheumatol
2003;32:337–42.

18. Nogueira L, Sebbag M, Vincent C et al. Performance of two ELISAs

for antifilaggrin autoantibodies, using either affinity purified or
deiminated recombinant human filaggrin, in the diagnosis of
rheumatoid arthritis. Ann Rheum Dis 2001;60:882–7.

19. Vincent C, Nogueira L, Sebbag M et al. Detection of antibodies to

deiminated recombinant rat filaggrin by enzyme-linked immunosor-
bent assay: a highly effective test for the diagnosis of rheumatoid
arthritis. Arthritis Rheum 2002;46:2051–8.

20. Union A, Meheus L, Humbel RL et al. Identification of citrullinated

rheumatoid arthritis-specific epitopes in natural filaggrin relevant for

antifilaggrin autoantibody detection by line immunoassay. Arthritis
Rheum 2002;46:1185–95.

21. Nielen MM, van der Horst AR, van Schaardenburg D et al.

Antibodies to citrullinated human fibrinogen (ACF) have diagnostic
and prognostic value in early arthritis. Ann Rheum Dis 2005;64:
1199–204.

22. Schellekens GA, Visser H, de Jong BA et al. The diagnostic

properties of rheumatoid arthritis antibodies recognizing a cyclic
citrullinated peptide. Arthritis Rheum 2000;43:155–63.

23. van Gaalen FA, Visser H, Huizinga TW. A comparison of the

diagnostic accuracy and prognostic value of the first- and second
anti-cyclic citrullinated peptides autoantibody (CCP1 and CCP2)
tests for rheumatoid arthritis. Ann Rheum Dis 2005, in press.

24. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, Maciel S.

Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid
arthritis. Ann Intern Med 2003;139:234–5.

25. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of

anti-CCP antibodies. Am Clin Lab 2002;21:34–6.

26. Suzuki K, Sawada T, Murakami A et al. High diagnostic

performance of ELISA detection of antibodies to citrullinated
antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:
197–204.

27. Dubucquoi S, Solau-Gervais E, Lefranc D et al. Evaluation of anti-

citrullinated filaggrin antibodies as hallmarks for the diagnosis of
rheumatic diseases. Ann Rheum Dis 2004;63:415–9.

28. de Rycke L, Peene I, Hoffman IE et al. Rheumatoid factor and anti-

citrullinated protein antibodies in rheumatoid arthritis: diagnostic
value, associations with radiological progression rate, and extra-
articular manifestations. Ann Rheum Dis 2004;63:1587–93.

29. Vallbracht I, Rieber J, Oppermann M et al. Diagnostic and clinical

value of anti-cyclic citrullinated peptide antibodies compared with
rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis
2004;63:1079–84.

30. Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C et al. Second

generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies
can replace other anti-filaggrin antibodies and improve rheumatoid
arthritis diagnosis. Scand J Rheumatol 2004;33:218–20.

31. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients

with rheumatic diseases. Ann Rheum Dis 2003;62:870–4.

32. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly

specific marker for (early) rheumatoid arthritis. Clin Appl Immunol
Rev 2004;4:239–62.

33. Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value

of anti-cyclic citrullinated peptide antibody in patients with recent-
onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.

34. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use

of anti-citrullinated peptide and anti-RA33 antibodies in distinguish-
ing erosive arthritis in patients with systemic lupus erythematosus
and rheumatoid arthritis. Ann Rheum Dis 2001;60:67–8.

35. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence

of antibodies to cyclic citrullinated peptide in sera of patients with
hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum
2004;50:2305–8.

36. Bombardieri M, Alessandri C, Labbadia G et al. Role of anti-cyclic

citrullinated peptide antibodies in discriminating patients with
rheumatoid

arthritis

from

patients

with

chronic

hepatitis

C

infection-associated polyarticular involvement. Arthritis Res Ther
2004;6:R137–41.

37. Lopez-Hoyos M, Ruiz DA, Blanco R et al. Clinical utility of anti-

CCP antibodies in the differential diagnosis of elderly-onset
rheumatoid arthritis and polymyalgia rheumatica. Rheumatology
2004;43:655–7.

38. Salvador G, Gomez A, Vinas O et al. Prevalence and clinical

significance of anti-cyclic citrullinated peptide and antikeratin
antibodies in palindromic rheumatism. An abortive form of
rheumatoid arthritis? Rheumatology 2003;42:972–5.

39. Gottenberg JE, Mignot S, Nicaise-Rolland P et al. Prevalence of

anti-cyclic citrullinated peptide and anti- keratin antibodies in

24

A. J. W. Zendman et al.

patients with primary Sjogren’s syndrome. Ann Rheum Dis 2004;
64:114–7.

40. Vander Cruyssen B, Hoffman IE, Zmierczak H et al. Anti-

citrullinated peptide antibodies may occur in patients with psoriatic
arthritis. Ann Rheum Dis 2005;64:1145–9.

41. Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and

other relapsing arthritis. Best Pract Res Clin Rheumatol 2004;18:
647–61.

42. Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS et al. Prognostic

factors for the development of rheumatoid arthritis and other
connective tissue diseases in patients with palindromic rheumatism.
J Rheumatol 1999;26:540–5.

43. Nielen MM, van Schaardenburg D, Reesink HW et al. Specific

autoantibodies precede the symptoms of rheumatoid arthritis: a
study of serial measurements in blood donors. Arthritis Rheum
2004;50:380–6.

44. Rantapa¨a¨-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies

against cyclic citrullinated peptide and IgA rheumatoid factor predict
the development of rheumatoid arthritis. Arthritis Rheum 2003;
48:2741–9.

45. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al.

Autoantibodies to cyclic citrullinated peptides predict progression
to rheumatoid arthritis in patients with undifferentiated arthritis:
a prospective cohort study. Arthritis Rheum 2004;50:709–15.

46. Soderlin MK, Kastbom A, Kautiainen H et al. Antibodies against

cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric
matrix protein (COMP) in very early arthritis: relation to diagnosis
and disease activity. Scand J Rheumatol 2004;33:185–8.

47. Zendman AJ, Vossenaar ER, van Venrooij WJ. Autoantibodies to

citrullinated (poly)peptides: a key diagnostic and prognostic marker
for rheumatoid arthritis. Autoimmunity 2004;37:295–9.

48. Forslind K, Ahlme´n M, Eberhardt K et al. Prediction of radio-

logical outcome in early RA in clinical practice: role of antibodies to
citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090–5.

49. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP

antibody test predicts the disease course during three years in early
rheumatoid arthritis (the TIRA project). Ann Rheum Dis 2004;63:
1085–9.

50. Ro¨nnelid J, Wick MC, Lampa J et al. Longitudinal analysis of

anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year
follow-up in early rheumatoid arthritis: anti-CP status is a stable
phenotype

that

predicts

worse

disease

activity

and

greater

radiological progression. Ann Rheum Dis 2005, in press.

51. Berglin E, Padyukov L, Sundin E et al. A combination of

autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1
locus antigens is strongly associated with future onset of rheumatoid
arthritis. Arthritis Res Ther 2004;6:R303–8.

52. van Gaalen FA, van Aken J, Huizinga TW et al. Association

between

HLA

class

II

genes

and

autoantibodies

to

cyclic

citrullinated peptides (CCPs) influences the severity of rheumatoid
arthritis. Arthritis Rheum 2004;50:2113–21.

53. Lindqvist E, Eberhardt K, Bendtzen K et al. Prognostic laboratory

markers of joint damage in rheumatoid arthritis. Ann Rheum Dis
2005;64:196–201.

54. Raza K, Breese M, Nightingale P et al. Predictive value of antibodies

to

cyclic

citrullinated

peptide

in

patients

with

very

early

inflammatory arthritis. J Rheumatol 2005;32:231–8.

55. Maddali-Bongi S, Manetti R, Melchiorre D et al. Anti-cyclic

citrullinated peptide antibodies are highly associated with severe
bone lesions in rheumatoid arthritis anti-CCP and bone damage in
RA. Autoimmunity 2004;37:495–501.

56. Gossec L, Dougados M, Goupille P et al. Prognostic factors for

remission in early rheumatoid arthritis: a multiparameter prospective
study. Ann Rheum Dis 2004;63:675–80.

57. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and

methotrexate in the treatment of rheumatoid arthritis. Anti-tumor
necrosis factor trial in rheumatoid arthritis with concomitant therapy
study group. N Engl J Med 2000;343:1594–602.

58. Maini RN, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-

tumour necrosis factor alpha monoclonal antibody) versus placebo
in rheumatoid arthritis patients receiving concomitant methotrexate:
a randomised phase III trial. ATTRACT Study Group. Lancet 1999;
354:1932–9.

59. Bobbio-Pallavicini F, Alpini C, Caporali R et al. Autoantibody

profile in rheumatoid arthritis during long-term infliximab treatment.
Arthritis Res Ther 2004;6:R264–72.

60. Nissinen R, Leirisalo-Repo M, Peltomaa R et al. Cytokine and

chemokine receptor profile of peripheral blood mononuclear cells
during treatment with infliximab in patients with active rheumatoid
arthritis. Ann Rheum Dis 2004;63:681–7.

61. Alessandri C, Bombardieri M, Papa N et al. Decrease of anti-cyclic

citrullinated peptide antibodies and rheumatoid factor following
anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is
associated with clinical improvement. Ann Rheum Dis 2004;63:
1218–21.

62. de Rycke L, Verhelst X, Kruithof E et al. Rheumatoid factor,

but not anti-citrullinated protein antibodies, is modulated by
infliximab treatment in rheumatoid arthritis. Ann Rheum Dis
2004;64:299–302.

63. Caramaschi P, Biasi D, Tonolli E et al. Antibodies against cyclic

citrullinated peptides in patients affected by rheumatoid arthritis
before and after infliximab treatment. Rheumatol Int 2005, in press.

64. Mikuls TR, O’Dell JR, Stoner JA et al. Association of rheumatoid

arthritis treatment response and disease duration with declines in
serum levels of IgM rheumatoid factor and anti-cyclic citrullinated
peptide antibody. Arthritis Rheum 2004;50:3776–82.

65. Chapuy-Regaud S, Sebbag M, Nachat R et al. Peptidylarginine

deiminase

isoforms

expressed

in

the

synovial

membrane

of

rheumatoid arthritis patients. Arthritis Res Ther 2003;5(Suppl. 1):5.

66. Vossenaar ER, Radstake TR, van der Heijden A et al. Expression

and activity of citrullinating PAD enzymes in monocytes and
macrophages. Ann Rheum Dis 2004;63:373–81.

67. Vossenaar ER, Smeets TJ, Kraan MC et al. The presence of

citrullinated proteins is not specific for rheumatoid synovial tissue.
Arthritis Rheum 2004;50:3485–94.

68. Chapuy-Regaud S, Sebbag M, Baeten D et al. Fibrin deimination in

synovial tissue is not specific for rheumatoid arthritis but commonly
occurs during synovitides. J Immunol 2005;174:5057–64.

69. Hill JA, Southwood S, Sette A et al. The conversion of arginine to

citrulline allows for a high-affinity peptide interaction with the
rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II
molecule. J Immunol 2003;171:538–41.

70. Vossenaar ER, Zendman AJ, van Venrooij WJ. Citrullination, a

possible functional link between susceptibility genes and rheumatoid
arthritis. Arthritis Res Ther 2004;6:1–5.

71. Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks

that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther
2004;6:107–11.

72. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid

arthritis. Nat Rev Drug Discov 2003;2:473–88.

73. O’Dell JR. Treating rheumatoid arthritis early: a window of

opportunity? Arthritis Rheum 2002;46:283–5.

74. Robinson WH, DiGennaro C, Hueber W et al. Autoantigen

microarrays

for

multiplex

characterization

of

autoantibody

responses. Nat Med 2002;8:295–301.

75. Tampoia M, Brescia V, Fontana A et al. Proteomic: New advances

in the diagnosis of rheumatoid arthritis. Clin Chim Acta 2005;
357:219–25.

Diagnostic potential of CCP2 test for RA

25